TP-3 immunotoxins improve antitumor activity in mice with osteosarcoma

Clinical Orthopaedics and Related Research

Volumn 430, Issue , 2005, Pages 142-148

  Onda, Masanori ^a,b   Bruland, Øyvind S ^c   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BIVALENT IMMUNOTOXIN TP 3(DSFV) PE38; IMMUNOTOXIN; IMMUNOTOXIN TP 3(DSFV) PE38; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG DESIGN; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL;

EID: 11844288251     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/01.blo.0000137544.30200.b6     Document Type: Article

References (37)

1. Bacci G, Bertoni F, Longhi A, et al: Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity: Histologic response to preoperative chemotherapy correlates with histologic sub-type of the tumor. Cancer 97:3068-3075, 2003.
2. Bera TK, Onda M, Brinkmann U, Pastan I: A bivalent disulfide-stabilized Fv with improved antigen binding to erb32. J Mol Biol 281:475-483, 1998.
3. Bera TK, Viner J, Brinkmann M, Pastan I: Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2, Cancer Res 59:4018-4022, 1999.
4. Bera TK, Williams-Gould J, Beers R, Chowdhury P, Pastan I: Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer. Mol Cancer Ther 1:79-84, 2001.
5. Brinkmann U, Pai LH, FitzGerald DJ, Willingham M, Pastan I: B3(Fv)-PE38KDEL: A single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci USA 88:8616-8620, 1991.
6. Bruland OS, Fodstad O, Funderud S, Pihl A: New monoclonal antibodies specific for human sarcomas. Int J Cancer 38:27-31, 1986.
7. Bruland OS, Fodstad O, Stenwig AE, Pihl A: Expression and characteristics of a novel human osteosarcoma-associated cell surface antigen. Cancer Res 48:5302-5309, 1988.
8. Bruland OS, Pihl A: On the current management of osteosarcoma: A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 33:1725-1731, 1997.
9. Buchner J, Pastan I, Brinkmann U: A method for increasing the yield of properly folded recombinant fusion proteins: Single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem 205:263-270, 1992.
10. Ek O, Waurzyniak B, Myers DE, Uckun FM: Antitumor activity of TP3(anti-p80)-pokeweed antiviral protein immunotoxin in hamster cheek pouch and severe combined immunodeficient mouse xenograft models of human osteosarcoma. Clin Cancer Res 4:1641-1647, 1998.
11. Fodstad O, Brogger A, Bruland O, et al: Characteristics of a cell line established from a patient with multiple osteosarcoma, appearing 13 years after treatment for bilateral retinoblastoma. Int J Cancer 38:33-40, 1986.
12. Gamberi G, Benassi MS, Bohling T, et al: C-myc and c-fos in human osteosarcoma: Prognostic value of mRNA and protein expression. Oncology 55:556-563, 1998.
13. Gibbs Jr CP, Weber K, Scarborough MT: Malignant bone tumors. Instr Course Lect 51:413-428, 2002.
14. Glasser DB, Lane JM, Huvos AG, Marcove RC, Rosen G: Survival, prognosis, and therapeutic response in osteogenic sarcoma: The Memorial Hospital experience. Cancer 69:698-708, 1992.
15. Haines DM, Bruland OS: Immunohistochemical detection of osteosarcoma-associated antigen in canine osteosarcoma. Anticancer Res 9:903-907, 1989.
16. Hauben EI, Weeden S, Pringle J, Van Marck EA, Hogendoorn PC: Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer 38:1218-1225, 2002.
17. Haunschild J, Faro H-P, Pack P, Pluckthun A: Pharmacokinetic properties of bivalent miniantibodies and comparison to other immunoglobulin forms. Antibody Immunoconjugates and Radiopharmaceuticals 8:111-128, 1995.
18. Holliger P, Prospero T, Winter G: Diabodies:" Small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90:6444-6448, 1993.
19. Hollinger P, Winter G: Engineering bispecific antibodies. Curr Opin Biotechnol 4:446-449, 1993.
20. Hwang J, FitzGerald DJ, Adhya S, Pastan I: Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell 48:129-136, 1987.
21. Kreitman RJ, Pastan I: Accumulation of a recombinant immunotoxin in a tumor in vivo: Fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res 58:968-975, 1998.
22. Mallender WD, Ferreira ST, Voss Jr EJ, Coelho-Sampaio T: Interactive-site distance and solution dynamics of a bivalent-bispecific single-chain antibody molecule. Biochemistry 33:10100-10108, 1994.
23. Mansfield E, Amlot P, Pastan I, FitzGerald DJ: Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood 90:2020-2026, 1997.
24. Neglia JP, Friedman DL, Yasui Y, et al: Second malignant neoplasms in five-year survivors of childhood cancer: Childhood cancer survivor study. J Natl Cancer Inst 93:618-629, 2001.
25. Onda M, Kreitman R, Vasmatzis G, Lee B, Pastan I: Reduction of the nonspecific animal toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point. J Immunol 163:6072-6077, 1999.
26. Onda M, Matsuda S, Higaki S, et al: ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 77:71-78, 1996.
27. Onda M, Nagata S, Tsutsumi Y, et al: Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. Cancer Res 61:5070-5077, 2001.
28. Onda M, Olafsen T, Tsutsumi Y, Bruland OS, Pastan I: Cytotoxicity of antiosteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and a truncated Pseudomonas exotoxin A. J Immunother 24:144-150, 2001.
29. Onda M, Wang Q, Guo H, Cheung NK, Pastan I: In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res 64:1419-1424, 2004.
30. Onda M, Willingham M, Wang QC, et al: Inhibition of TNF-α produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2. J Immunol 165:7150-7156, 2000.
31. Pluckthun A: Mono- and bivalent antibody fragments produced in Esherichia coli: Engineering, folding and antigen binding. Immunol Rev 130:151-188, 1992.
32. Provisor AJ, Ettinger LJ, Nachman JB, et al: Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the Children's Cancer Group. J Clin Oncol 15:76-84, 1997.
33. Reiter Y, Brinkmann U, Webber KO, et al: Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: Improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. Protein Eng 7:697-704, 1994.
34. Reiter Y, Pai LH, Brinkmann U, Wang QC, Pastan I: Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Cancer Res 54:2714-2718, 1994.
35. Studier FW, Moffatt BA: Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J Mol Biol 189:113-130, 1986.
36. Thompson Jr RC, Cheng EY, Clohisy DR, et al: Results of treatment for metastatic osteosarcoma with neoadjuvant chemotherapy and surgery. Clin Orthop 397:240-247, 2002.
37. Yokota T, Milenic DE, Whitlow M, Schlom J: Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52:3402-3408, 1992.